<DOC>
	<DOC>NCT00497315</DOC>
	<brief_summary>The aim of this study is to evaluate if the multi modality treatment pemetrexed combined with cisplatin and radiotherapy can lead to a better tumor control and/or a better side-effect profile in patients with locally advanced NSCLC. Patients will be randomized between 3 cycles of induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy followed by 3 cycles of adjuvant combination chemotherapy.</brief_summary>
	<brief_title>Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>cytological or histological proven NSCLC unresectable stage III NSCLC presence of at least one measurable lesion (RECIST criteria) adequate haematological, renal and hepatic function adequate lung function reserve good condition, weight loss &lt;10 % over previous 6 months, life expectancy &gt; 3 months previous chemo or radiotherapy for NSCLC distant metastasis or a malignant pleural or pericardial effusion second active primary malignancy or serious concomitant medical disease interstitial lung disease autoimmune systemic disease with potential involvement of the lungs inability to interrupt aspirin or other nonsteroidal antiinflammatory agents for a 5day period concomitant use of amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>locally advanced NSCLC</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>lung cancer</keyword>
</DOC>